Vat-brown-3 is a brown dye.

VAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for VAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAT1L Human Pre-designed siRNA Set A contains three designed siRNAs for VAT1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAV1 Human Pre-designed siRNA Set A contains three designed siRNAs for VAV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAV2 Human Pre-designed siRNA Set A contains three designed siRNAs for VAV2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAV3 Human Pre-designed siRNA Set A contains three designed siRNAs for VAV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAX1 Human Pre-designed siRNA Set A contains three designed siRNAs for VAX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VAX2 Human Pre-designed siRNA Set A contains three designed siRNAs for VAX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases[1].

VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases[1].

VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases[1].

VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases[1].

VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases[1].

VBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for VBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCAM1 Human Pre-designed siRNA Set A contains three designed siRNAs for VCAM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCAN Human Pre-designed siRNA Set A contains three designed siRNAs for VCAN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCL Human Pre-designed siRNA Set A contains three designed siRNAs for VCL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCP Human Pre-designed siRNA Set A contains three designed siRNAs for VCP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vcp Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vcp gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vcp Rat Pre-designed siRNA Set A contains three designed siRNAs for Vcp gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCPIP1 Human Pre-designed siRNA Set A contains three designed siRNAs for VCPIP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCX Human Pre-designed siRNA Set A contains three designed siRNAs for VCX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCX2 Human Pre-designed siRNA Set A contains three designed siRNAs for VCX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCX3A Human Pre-designed siRNA Set A contains three designed siRNAs for VCX3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VCY Human Pre-designed siRNA Set A contains three designed siRNAs for VCY gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VD4162 (Compound 8b) is a macrocyclic inhibitor of serine proteases. VD4162 can significantly improve potency for all four target enzymes TMPRSS2 (IC50 = 3.7 nM), HGFA(IC50 = 3.3 nM), matriptase (IC50 = 2.9 nM), and hepsin (IC50 = 0.54 nM). VD4162 can be used for the research of cancer[1].

VD5123 is a serine protease inhibitor. VD5123 inhibits TMPRS2, HGFA, matriptase, hepsin with IC50s of 15, 3980, 140, 37 nM respectively. VD5123 can be used for antiviral research, such as SARS-CoV-2 and broad panel of coronaviruses and influenza viruses[1].

VDAC1 Human Pre-designed siRNA Set A contains three designed siRNAs for VDAC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VDAC2 Human Pre-designed siRNA Set A contains three designed siRNAs for VDAC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VDAC3 Human Pre-designed siRNA Set A contains three designed siRNAs for VDAC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VDR Human Pre-designed siRNA Set A contains three designed siRNAs for VDR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vdr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vdr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vdr Rat Pre-designed siRNA Set A contains three designed siRNAs for Vdr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFA Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFB Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFC Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFD Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFR-2 IN-41 (Compound 8) is a VEGFR-2 inhibitor with IC50 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity[1].

VEGFR-2-IN-42 (compound 8c) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-42 shows anti-proliferative effect against MCF7 cells with the IC50 of 25 µM[1].

VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC50 of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research[1].

VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC50 value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC50 of 920 nM[1].

Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent[1]